Table 1.
Characteristics of the cohort of patients with inflammatory bowel disease.
| Characteristics | N = 3953 | % or mean (SD) |
|---|---|---|
| Age (years) | 3953 | 47.3 (15.3) |
| IBD type | ||
| Crohn’s disease | 2541 | 65% |
| Ulcerative colitis/indeterminate colitis | 1354 | 34% |
| Gender (% female) | 2698 | 69% |
| Comorbidities | ||
| Chronic lung disease (asthma, COPD) (% yes) | 650 | 16% |
| Diabetes (% yes) | 176 | 4% |
| Kidney disease (% yes) | 118 | 3% |
| History of organ transplantation (% yes) | 16 | 0% |
| Active cancer (% yes) | 59 | 1% |
| Education (% >high school) | 2935 | 95% |
| Race (%) | ||
| Caucasian/other | 3903 | 99% |
| African American | 50 | 1% |
| Current smoking (% yes) | 83 | 4% |
| Obesity (BMI ≥30) (% yes) | 733 | 19% |
| Medications at enrollment (% yes)a | ||
| Anti-TNF | 1481 | 38% |
| Vedolizumab | 461 | 12% |
| Ustekinumab | 435 | 11% |
| Immunomodulator (IMM)b | 843 | 22% |
| Combination therapy (anti-TNF + IMM) | 389 | 10% |
| Corticosteroids (systemic) | 384 | 10% |
| Tofacitinib | 56 | 2% |
| 5-ASA | 943 | 24% |
| Any immunosuppression (% yes) | 2782 | 70% |
| Duration of follow-up (days) | 3953 | 211.6 (156.9) |
Abbreviations: 5-ASA, 5-aminosalicylate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease.
Anti-TNF (anti-tumor necrosis factor alpha), IMM, and combination groups not mutually exclusive.
Methotrexate, azathioprine, or 6-mercaptopurine.